Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573264 | 0.89 | MEN1 (0.57) | MEN1KMT2ATAAR1IDO1AGXT | |
| SCHEMBL2794522 | 0.87 | MEN1 (0.55) | MEN1KMT2ATAAR1IDO1AGXT | |
| SCHEMBL4399626 | 0.80 | TAAR1 (0.74) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL17210451 | 0.80 | MEN1 (0.47) | MEN1KMT2ATAAR1IDO1AGXT | |
| SCHEMBL5314627 | 0.80 | TAAR1 (0.57) | MEN1KMT2ATAAR1IDO1AGXT | |
| SCHEMBL7718853 | 0.80 | MEN1 (0.80) | MEN1KMT2ATAAR1MAOBTDP1 | |
| SCHEMBL5537172 | 0.80 | TAAR1 (0.57) | MEN1KMT2ATAAR1IDO1AGXT | |
| SCHEMBL332680 | 0.79 | ENPP2 (0.53) | MEN1KMT2ATAAR1IDO1AGXT | |
| SCHEMBL5240585 | 0.76 | TAAR1 (0.68) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL24289005 | 0.76 | MEN1 (0.73) | MEN1KMT2AIDO1SMN1; SMN2CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974902-B | 2-Cyano-1-phenyl vinyl boric acid pinacol ester and preparation method and application thereof | 韶远科技（上海)有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4185379-A1 | THERAPEUTIC AGENTS TARGETING GPR35 | Prometheus Biosciences, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230151017-A1 | THERAPEUTIC AGENTS TARGETING GPR35 | PROMETHEUS BIOSCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151017-A1 | THERAPEUTIC AGENTS TARGETING GPR35 | PROMETHEUS BIOSCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115974902-A | 2-cyano-1-phenyl vinyl boronic acid pinacol ester and preparation method and application thereof | 韶远科技（上海)有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022020617-A1 | THERAPEUTIC AGENTS TARGETING GPR35 | PROMETHEUS BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| WO-2017060488-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2017-04-13 | — | — | WO | disclosed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| CN-1909908-A | Pyrazolo [1, 5-a ] pyrimidin-7-yl-amine derivatives for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006044497-A2 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER’S DISEASE | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2004011427-A2 | SUBSTITUTED BENZANILIDES AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | MEN1 1174/4885KMT2A 1110/4885TAAR1 1865/4885 |
| US-20230151017-A1 | THERAPEUTIC AGENTS TARGETING GPR35 | GPR35, GPR68, GPR65 | MEN1 3802/4885KMT2A 4043/4885TAAR1 836/4885 |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | AADAC, ME2, HTRA2 | MEN1 4052/4885KMT2A 476/4885TAAR1 3166/4885 |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | BACE1, BACE2, APP | MEN1 1616/4885KMT2A 3934/4885TAAR1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.